Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126843 | 0.99 | P2RX7 (0.71) | P2RX7ABCB11 | |
| SCHEMBL4124554 | 0.96 | P2RX7 (0.75) | P2RX7ABCB11 | |
| SCHEMBL7083604 | 0.90 | P2RX7 (0.58) | P2RX7ABCB11 | |
| SCHEMBL7085328 | 0.89 | P2RX7 (0.58) | P2RX7ABCB11 | |
| SCHEMBL7082142 | 0.87 | P2RX7 (0.59) | P2RX7ABCB11 | |
| SCHEMBL4135392 | 0.87 | P2RX7 (0.76) | P2RX7ABCB11 | |
| SCHEMBL4129882 | 0.86 | P2RX7 (0.78) | P2RX7ABCB11 | |
| SCHEMBL4126448 | 0.85 | P2RX7 (0.74) | P2RX7ABCB11 | |
| SCHEMBL4129123 | 0.84 | P2RX7 (0.86) | P2RX7ABCB11 | |
| SCHEMBL7662131 | 0.84 | P2RX7 (0.71) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | claimed |
| EP-1862451-A1 | Adamantane derivatives for the treatment of inflammatory diseases | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | claimed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | claimed |
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | claimed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | claimed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | claimed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | claimed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | claimed |
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20090137191-A1 | COPPER CMP POLISHING PAD CLEANING COMPOSITION COMPRISING OF AMIDOXIME COMPOUNDS | EKC TECHNOLOGY, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090130849-A1 | CHEMICAL MECHANICAL POLISHING AND WAFER CLEANING COMPOSITION COMPRISING AMIDOXIME COMPOUNDS AND ASSOCIATED METHOD FOR USE | EKC TECHNOLOGY, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
| WO-2000050374-A1 | REDUCTION OF THE CARBONYL VALUE OF CARBOXYLIC ACIDS AND DERIVATIVES OF CARBOXYLIC ACIDS | COGNIS CORPORATION (US) | 2000-08-31 | — | — | WO | disclosed |
| EP-0640586-B1 | STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF | MORINAGA MILK INDUSTRY CO LTD (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-5589506-A | ENZYME INHIBITORS FOR LIPOXYGENASE | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0640586-A1 | STILBENE DERIVATIVE AND STILBENE ANALOG DERIVATIVE, AND USE THEREOF | MORINAGA MILK INDUSTRY CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | P2RX7 1500/4885ABCB11 399/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | P2RX7 1692/4885ABCB11 558/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | P2RX7 1020/4885ABCB11 2799/4885 |
| US-20090137191-A1 | COPPER CMP POLISHING PAD CLEANING COMPOSITION COMPRISING OF AMIDOXIME COMPOUNDS | PADI2, PADI4, PADI3 | P2RX7 230/4885ABCB11 4150/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | P2RX7 1692/4885ABCB11 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.